報價延遲最少15分鐘:2025/05/15 18:45 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.1946 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.60/-10.80
|
|
企業價值
4.20M
|
| 資產負債 |
|
每股賬面淨值
-0.01
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
0.01
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/05/15 18:45 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. The Company operates in one reportable segment, which includes activities related to advancing the development of its concussion drug, ONP-002. |